- Company
- Chong Kun Dang strengthens its oncology business
- by Kim, Jin-Gu Feb 27, 2025 05:57am
- Chong Kun Dang is tightening the reins on its oncology business. It recently acquired the right for the liver cancer drugs ‘Nexavar (sorafenib)' and ‘Stivarga (regorafenib)' and neutropenia drug ‘Neulapeg (pegfilgrastim)' in the recent month. The company expects the drugs to create synergy with its existing pipeline of anti-cancer dru
- Company
- LigaChem Bio expands partnership with Wuxi XDC
- by Cha, Jihyun Feb 27, 2025 05:57am
- LigaChem Biosciences announced on the 26th that it has signed an expanded memorandum of understanding (MOU) with Wuxi XDC to develop a next-generation antibody-drug conjugate (ADC) drug. This agreement expands the collaboration from clinical sample production to research and development in addition to the 2021 agreement that had been made be
- Policy
- NA starts Special Act to support the pharma and bio industry
- by Lee, Jeong-Hwan Feb 27, 2025 05:56am
- The National Assembly is pushing for the enactment of a special law to bring together the capabilities at the national level to promote and foster the biopharmaceutical industry. The policy agenda includes the establishment of a basic plan every 5 years, the establishment of a Pharmaceutical Biohealth Innovation Committee, and the provis
- Company
- Dongwha makes record sales record for 4 consecutive years
- by Kim, Jin-Gu Feb 26, 2025 06:30am
- Dongwha Pharmaceutical has broken its sales record for 4 consecutive years. The company's active overseas investment and entry into new businesses are cited as the driving forces behind the record sales streak. In particular, the Vietnamese pharmacy chain it acquired in 2023 has contributed greatly to the expansion of the company's business.
- Opinion
- [Reporter's View] Gov't OKs JAK inhibitor drug switching
- by Eo, Yun-Ho Feb 26, 2025 06:30am
- It has been a flexible and swift measure. Drug-switching between JAK inhibitors and biological agents for the treatment of severe atopic dermatitis will be reimbursed starting in March. The Ministry of Health and Welfare (MOHW) issued an administration notice of a partial revision draft of the pharmaceutical long-term care reimbursement requ
- Company
- SK Bioscience will start a global trial for its mRNA vaccine
- by Cha, Jihyun Feb 26, 2025 06:29am
- SK Bioscience's messenger ribonucleic acid (mRNA) vaccine has entered full-scale clinical trials. SK Bioscience announced on the 25th that it has begun Phase I/II global clinical trials of GBP560, a Japanese encephalitis mRNA vaccine candidate. The Phase I/II clinical trial will involve 402 healthy adults living in Australia and New Ze
- Company
- Celltrion tops KRW 1T in 2024 sales
- by Chon, Seung-Hyun Feb 26, 2025 06:29am
- Celltrion's sales and operating profit are reported to be the highest in history due to expanded sales of biosimilars. Its sales exceeded KRW 1 trillion in both North American and European markets. According to the Financial Supervisory Service (FSS), Celltrion's operating profit for last year was KRW 1.2110 trillion, up 89.7% from the previo
- Company
- Samsung Bioepis launches Stelara biosimilar Pyzchiva in US
- by Whang, byung-woo Feb 26, 2025 06:29am
- Samsung Bioepis announced on the 25th that its autoimmune disease treatment Pyzchiva (ustekinumab) has been launched in the US through its marketing partner Sandoz. Stelara’s biosimilar Pyzchiva is Janssen’s treatment for autoimmune diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Stelara’s a
- Policy
- Priority mkt authorization for Trajenta generics ends
- by Lee, Tak-Sun Feb 25, 2025 05:57am
- As the priority marketing authorization for the generic version of Trajenta (linagliptin), a DPP-4 inhibitor used to treat diabetes, launched last year will end on March 8, generics that have been waiting for 10 months will be launched. The list of generics to be launched includes Hanmi Pharmaceutical and Genuone Sciences. According to
- Policy
- Only Rinvoq to undergo drug pricing reduction
- by Lee, Tak-Sun Feb 25, 2025 05:57am
- As the reimbursement of drug switching between biological agents and JAK inhibitors for the treatment of severe atopic dermatitis will be implemented next month, additional claim amounts are reported to be insignificant. Rinvoq ER Tab (AbbVie, upadacitinib) is the only product to see drug pricing reduction due to the expected additional
